A Fifty‐Two–Week, Randomized, Placebo‐Controlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis-Reference-Cited by-同舟云学术

A Fifty‐Two–Week, Randomized, Placebo‐Controlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis

Published:2019-05-28 Issue:7 Volume:71 Page:1101-1111
ISSN:2326-5191
Container-title:Arthritis & Rheumatology
language:en
Short-container-title:Arthritis Rheumatol

Author:

Deodhar Atul¹,Gensler Lianne S.²,Kay Jonathan³^ORCID,Maksymowych Walter P.⁴,Haroon Nigil⁵^ORCID,Landewé Robert⁶,Rudwaleit Martin⁷,Hall Stephen⁸,Bauer Lars⁹,Hoepken Bengt⁹,Peyrecave Natasha¹⁰,Kilgallen Brian¹¹,Heijde Désirée¹²

Affiliation:

1. Oregon Health & Science University Portland

2. University of California San Francisco

3. UMass Memorial Medical Center and University of Massachusetts Medical School Worcester

4. University of Alberta Edmonton Alberta Canada

5. University Health Network and University of Toronto Toronto Ontario Canada

6. Academic Medical Center and Zuyderland Medical Center Heerlen The Netherlands

7. Klinikum Bielefeld Bielefeld Germany

8. Cabrini Medical CentreMonash University, and Emeritus Research Melbourne Victoria Australia

9. UCB Pharma Monheim am Rhein Germany

10. UCB Pharma Brussels Belgium

11. UCB Pharma Raleigh North Carolina

12. Leiden University Medical Center Leiden The Netherlands

Funder

UCB Pharma

Publisher

Wiley

Subject

Immunology,Rheumatology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/art.40866

Reference37 articles.

1. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study

2. Rapid improvements in patient‐reported outcomes with certolizumab pegol in patients with axial spondyloarthritis, including ankylosing spondylitis and non‐radiographic axial spondyloarthritis: 24‐week results of a phase 3 double blind randomized placebo‐controlled study [abstract];Sieper J;Value Health,2013

3. Non‐radiographic axial spondyloarthritis and ankylosing spondylitis: what are the similarities and differences?;Baraliakos X;RMD Open,2015

4. Ankylosing Spondylitis and Axial Spondyloarthritis

5. Should axial spondyloarthritis without radiographic changes be treated with anti-TNF agents?

Cited by 82 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment controversies in spondyloarthritis and psoriatic arthritis: focus on biologics and targeted therapies;Expert Review of Clinical Immunology;2024-07-29

2. Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b/3 trials;Annals of the Rheumatic Diseases;2024-07-08

3. Upadacitinib in Active Non‐radiographic Axial Spondyloarthritis: 1‐Year Data From a Double‐Blind, Randomized, Placebo‐Controlled, Phase 3 Trial;ACR Open Rheumatology;2024-05-15

4. Long-term clinical outcomes of certolizumab pegol treatment in non-radiographic axial spondyloarthritis stratified by baseline MRI and CRP status;RMD Open;2024-05

5. Certolizumab pegol in the treatment of axial spondyloarthritis;Immunotherapy;2024-03-26